Relationship between clinical remission of perianal fistulas in Crohn’s disease and serum adalimumab concentrations: A multi-center cross-sectional study

doi:10.3748/wjg.v28.i9.961

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 28, Issue 9

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5361)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-2) series.

Item

Count

PDF

292

WORD

141

HTML

2328

Figures (1-2)

266

Tables (1-2)

245

Sum=3272

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

559

Download

1530

Sum=2089

Mar 7, 2022 (publication date) through Jun 4, 2024

Times Cited of This Article

Times Cited (4)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Gastroenterol. Mar 7, 2022; 28(9): 961-972
Published online Mar 7, 2022. doi: 10.3748/wjg.v28.i9.961

Open in New Tab Full Size Figure Download Figure

Figure 1 Serum adalimumab concentrations according to clinical remission status.

Open in New Tab Full Size Figure Download Figure

Figure 2 Clinical remission according to quartiles of serum adalimumab concentrations.

Citation: Sirmai L, Pelletier AL, Gault N, Zallot C, Bouguen G, Bouchard D, Roland Nicaise P, Peyneau M, Sironneau S, Bittencourt MDC, Petitcollin A, Fernandez P, Roblin X, Siproudhis L, Abramowitz L. Relationship between clinical remission of perianal fistulas in Crohn’s disease and serum adalimumab concentrations: A multi-center cross-sectional study. World J Gastroenterol 2022; 28(9): 961-972
URL: https://www.wjgnet.com/1007-9327/full/v28/i9/961.htm
DOI: https://dx.doi.org/10.3748/wjg.v28.i9.961